Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination product candidate for the non-surgical treatment of high-grade cervical dysplasia. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. It has partnership with Artera for digital pathology AI test evaluation for bladder cancer. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, other European countries, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Часто задаваемые вопросы
В каком секторе работает Photocure ASA (PHCUF)?
Photocure ASA относится к сектору Здравоохранение.
Какова текущая цена акций Photocure ASA (PHCUF)?
По последним данным, цена акций Photocure ASA составляет 5,65 $, предыдущее закрытие — 5,65 $.
Какой коэффициент цена/прибыль (P/E) компании Photocure ASA (PHCUF)?
Текущий коэффициент P/E компании Photocure ASA составляет 18,23.
Выплачивает ли Photocure ASA (PHCUF) дивиденды?
Нет, Photocure ASA не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Photocure ASA (PHCUF)?
У компании Photocure ASA бета 0.343, что указывает на более низкую волатильность по сравнению с рынком в целом.
